Small-Cell Lung Cancer-Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Small-Cell Lung Cancer-Pipeline Review H1 2017” this report provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.
(EMAILWIRE.COM, June 20, 2017 ) Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 41, 33, 2, 32 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/small-cell-lung-cancer-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834385/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Advantagene Inc
Advenchen Laboratories LLC
Alchemia Ltd
Amgen Inc
Andarix Pharmaceuticals Inc
Aposense Ltd
Aprea AB
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene (Beijing) Co Ltd
Beta Pharma Inc
BioLineRx Ltd
Bionomics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
CellAct Pharma GmbH
Cellceutix Corp
Celldex Therapeutics Inc
Cornerstone Pharmaceuticals Inc
Critical Outcome Technologies Inc
CytRx Corp
Double Bond Pharmaceutical International AB
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Forty Seven Inc
G1 Therapeutics Inc
Genzyme Corp
GlaxoSmithKline Plc
Horizon Pharma Plc
Immunomedics Inc
Incyte Corp
Johnson & Johnson
Karyopharm Therapeutics Inc
Lindis Biotech GmbH
MabVax Therapeutics Holdings Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mirati Therapeutics Inc
MolMed SpA
Mologen AG
NanoSmart Pharmaceuticals Inc
Nektar Therapeutics
NewLink Genetics Corp
Nippon Kayaku Co Ltd
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Polaris Pharmaceuticals Inc
Recombio SL
Rexahn Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc
Sun Pharma Advanced Research Company Ltd
Sunshine Biopharma Inc
Syros Pharmaceuticals Inc
Tarveda Therapeutics Inc
Tesaro Inc
Teva Pharmaceutical Industries Ltd
United Therapeutics Corp
Verastem Inc
ViiV Healthcare Ltd
Xencor Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834385/discount
List of Tables
Number of Products under Development for Huntington Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Huntington Disease - Pipeline by Addex Therapeutics Ltd, H1 2017
Huntington Disease - Pipeline by AFFiRiS AG, H1 2017
Huntington Disease - Pipeline by Angita BV, H1 2017
Huntington Disease - Pipeline by Annexon Inc, H1 2017
Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by BioCrea GmbH, H1 2017
Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Celon Pharma SA, H1 2017
Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Huntington Disease - Pipeline by Evotec AG, H1 2017
Huntington Disease - Pipeline by Galenea Corp, H1 2017
Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
Huntington Disease - Pipeline by Horizon Pharma Plc, H1 2017
Huntington Disease - Pipeline by Immungenetics AG, H1 2017
Huntington Disease - Pipeline by InMed Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Ipsen SA, H1 2017
Huntington Disease - Pipeline by Kadmon Corp LLC, H1 2017
Huntington Disease - Pipeline by KineMed Inc, H1 2017
Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Living Cell Technologies Ltd, H1 2017
Huntington Disease - Pipeline by Medesis Pharma SA, H1 2017
Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Neuralstem Inc, H1 2017
Huntington Disease - Pipeline by Neurimmune Holding AG, H1 2017
Huntington Disease - Pipeline by Neurocrine Biosciences Inc, H1 2017
Huntington Disease - Pipeline by NeuroNascent Inc, H1 2017
Huntington Disease - Pipeline by New World Laboratories Inc, H1 2017
Huntington Disease - Pipeline by nLife Therapeutics SL, H1 2017
Huntington Disease - Pipeline by Novartis AG, H1 2017
Huntington Disease - Pipeline by NsGene A/S, H1 2017
Huntington Disease - Pipeline by Omeros Corp, H1 2017
Huntington Disease - Pipeline by Oryzon Genomics SA, H1 2017
Huntington Disease - Pipeline by Probiodrug AG, H1 2017
Huntington Disease - Pipeline by ProQR Therapeutics NV, H1 2017
Huntington Disease - Pipeline by PTC Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by QR Pharma Inc, H1 2017
Huntington Disease - Pipeline by reMYND NV, H1 2017
Huntington Disease - Pipeline by Sage Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Shire Plc, H1 2017
Huntington Disease - Pipeline by SOM Biotech SL, H1 2017
Huntington Disease - Pipeline by Spark Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Huntington Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
Huntington Disease - Pipeline by UniQure NV, H1 2017
Huntington Disease - Pipeline by Vaccinex Inc, H1 2017
Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Vitality Biopharma Inc, H1 2017
Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Huntington Disease - Pipeline by Voyager Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Vybion Inc, H1 2017
Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H1 2017
Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017
Huntington Disease - Dormant Projects, H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..2) , H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..3) , H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..4) , H1 2017
Huntington Disease - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834384/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 41, 33, 2, 32 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/small-cell-lung-cancer-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834385/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Advantagene Inc
Advenchen Laboratories LLC
Alchemia Ltd
Amgen Inc
Andarix Pharmaceuticals Inc
Aposense Ltd
Aprea AB
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene (Beijing) Co Ltd
Beta Pharma Inc
BioLineRx Ltd
Bionomics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
CellAct Pharma GmbH
Cellceutix Corp
Celldex Therapeutics Inc
Cornerstone Pharmaceuticals Inc
Critical Outcome Technologies Inc
CytRx Corp
Double Bond Pharmaceutical International AB
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Forty Seven Inc
G1 Therapeutics Inc
Genzyme Corp
GlaxoSmithKline Plc
Horizon Pharma Plc
Immunomedics Inc
Incyte Corp
Johnson & Johnson
Karyopharm Therapeutics Inc
Lindis Biotech GmbH
MabVax Therapeutics Holdings Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mirati Therapeutics Inc
MolMed SpA
Mologen AG
NanoSmart Pharmaceuticals Inc
Nektar Therapeutics
NewLink Genetics Corp
Nippon Kayaku Co Ltd
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Polaris Pharmaceuticals Inc
Recombio SL
Rexahn Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc
Sun Pharma Advanced Research Company Ltd
Sunshine Biopharma Inc
Syros Pharmaceuticals Inc
Tarveda Therapeutics Inc
Tesaro Inc
Teva Pharmaceutical Industries Ltd
United Therapeutics Corp
Verastem Inc
ViiV Healthcare Ltd
Xencor Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834385/discount
List of Tables
Number of Products under Development for Huntington Disease, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Huntington Disease - Pipeline by Addex Therapeutics Ltd, H1 2017
Huntington Disease - Pipeline by AFFiRiS AG, H1 2017
Huntington Disease - Pipeline by Angita BV, H1 2017
Huntington Disease - Pipeline by Annexon Inc, H1 2017
Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by BioCrea GmbH, H1 2017
Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Celon Pharma SA, H1 2017
Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Huntington Disease - Pipeline by Evotec AG, H1 2017
Huntington Disease - Pipeline by Galenea Corp, H1 2017
Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H1 2017
Huntington Disease - Pipeline by Horizon Pharma Plc, H1 2017
Huntington Disease - Pipeline by Immungenetics AG, H1 2017
Huntington Disease - Pipeline by InMed Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Ipsen SA, H1 2017
Huntington Disease - Pipeline by Kadmon Corp LLC, H1 2017
Huntington Disease - Pipeline by KineMed Inc, H1 2017
Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Living Cell Technologies Ltd, H1 2017
Huntington Disease - Pipeline by Medesis Pharma SA, H1 2017
Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by Neuralstem Inc, H1 2017
Huntington Disease - Pipeline by Neurimmune Holding AG, H1 2017
Huntington Disease - Pipeline by Neurocrine Biosciences Inc, H1 2017
Huntington Disease - Pipeline by NeuroNascent Inc, H1 2017
Huntington Disease - Pipeline by New World Laboratories Inc, H1 2017
Huntington Disease - Pipeline by nLife Therapeutics SL, H1 2017
Huntington Disease - Pipeline by Novartis AG, H1 2017
Huntington Disease - Pipeline by NsGene A/S, H1 2017
Huntington Disease - Pipeline by Omeros Corp, H1 2017
Huntington Disease - Pipeline by Oryzon Genomics SA, H1 2017
Huntington Disease - Pipeline by Probiodrug AG, H1 2017
Huntington Disease - Pipeline by ProQR Therapeutics NV, H1 2017
Huntington Disease - Pipeline by PTC Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by QR Pharma Inc, H1 2017
Huntington Disease - Pipeline by reMYND NV, H1 2017
Huntington Disease - Pipeline by Sage Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Shire Plc, H1 2017
Huntington Disease - Pipeline by SOM Biotech SL, H1 2017
Huntington Disease - Pipeline by Spark Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Stealth BioTherapeutics Inc, H1 2017
Huntington Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017
Huntington Disease - Pipeline by UniQure NV, H1 2017
Huntington Disease - Pipeline by Vaccinex Inc, H1 2017
Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Vitality Biopharma Inc, H1 2017
Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
Huntington Disease - Pipeline by Voyager Therapeutics Inc, H1 2017
Huntington Disease - Pipeline by Vybion Inc, H1 2017
Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H1 2017
Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H1 2017
Huntington Disease - Dormant Projects, H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..2) , H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..3) , H1 2017
Huntington Disease - Dormant Projects, H1 2017 (Contd..4) , H1 2017
Huntington Disease - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834384/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results